Table of Contents Author Guidelines Submit a Manuscript
Dermatology Research and Practice
Volume 2014 (2014), Article ID 409058, 6 pages
http://dx.doi.org/10.1155/2014/409058
Research Article

Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients

1St George’s, University of London, Cranmer Terrace, London SW17 0RE, UK
2The National Hospital for Neurology, 23 Queen Square, London WC1N 3BG, UK
3Department of Histopathology, Royal Sussex County Hospital, Eastern Road, Brighton BN2 5BE, UK
4Department of Renal Medicine and Transplantation, St George’s Healthcare NHS Trust, Blackshaw Road, London SW17 0QT, UK
5International Medical University, Jalan Jalil Perkasa 19, 57000 Kuala Lumpur, Malaysia

Received 15 July 2014; Revised 28 August 2014; Accepted 30 August 2014; Published 14 September 2014

Academic Editor: Jean Kanitakis

Copyright © 2014 Christopher D. Roche et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Transplant recipients require immunosuppression to prevent graft rejection. This conveys an increased risk of malignancy, particularly skin tumours. There is a need for up-to-date data for the South of England. Method. Pathology records were reviewed for 709 kidney transplant recipients on immunosuppression at our hospital from 1995 to 2008. Skin tumours were recorded/analysed. Results. Mean age at transplant was 46 years. Mean length of follow-up was 7.2 years and total follow-up was 4926 person-years. 53 (7.5%) patients (39/458 (8.5%) males and 14/251 (5.6%) females) developed ≥1 skin malignancy. Cumulative incidences of 4.0%, 7.5%, and 12.2% were observed for those with <5, <10, and ≥10 years follow-up, respectively. The rate was 45 tumours per 1000 person-years at risk. Additionally, 21 patients (3.0%) only had noninvasive tumours. 221 malignant skin tumours were found: 50.2% were SCCs, 47.1% BCCs, and 2.7% malignant melanomas. Mean years to first tumour were 5.8. Mean number of tumours per patient was 4, with mean interval of 12 months. Conclusions. Despite changes in transplantation practice during the time since the last data were published in this region, these findings are similar to previous studies. This adds to the evidence allowing clinicians to inform patients in this region of their risk.